Table 1 Characteristics of eligible studies in the meta-analysis.
Author | Year | Country | Study design | Study period | Patient | UCSI | Age (median) | Follow up (median) | outcome | Quality scores |
|---|---|---|---|---|---|---|---|---|---|---|
Zhang | 2015 | China | Cohort study | 2008–2011 | 253 RCC | 10 | 62.5 | 32.3 months | OS | 8 |
Brookman-May | 2011 | Europe and USA | Cohort study | 1984–2008 | 670 RCC (pT2) | 75 | 59.4 | 51 months | CSS | 8 |
Palapattu | 2003 | USA | Cohort study | 1989–1999 | 895 RCC | 124 | 59 | 31 months | OS | 9 |
Klatte | 2009 | USA | Cohort study | 1985–2007 | 158 pRCC | 29 | 61.9 | 38 months | CSS | 7 |
Margulis | 2007 | USA | Cohort study | 1990–2006 | 365 RCC (pT3a) | 34 | 58.2 | 22.5 months | CSS | 8 |
Klatte | 2007 | USA | Cohort study | 1985–2006 | 321 RCC (pT3) | 112 | 60.9 | 28 months | CSS | 7 |
Ornellas | 2012 | Brazil | Cohort study | 2004–2010 | 227 RCC | 38 | 60 | 28 months | RFS | 8 |
Shi | 2014 | China | Cohort study | 2000–2010 | 173 ccRCC | 28 | 53 | 61.4 months | CSS | 9 |
Klatte | 2007 | USA | Cohort study | 1985–2005 | 519 RCC (pT1+pT2) | 39 | 61 | 49 months | RFS | 8 |
Cho | 2009 | Korea | Cohort study | 1984–2007 | 299 ccRCC (pT1+pT2) | 42 | 56 | 52.3 months | CSS, RFS | 9 |
Terrone | 2004 | Italy | Cohort study | 1983–1999 | 671 RCC | 59 | 60.4 | 59 months | OS, CSS | 9 |
Sameh | 2012 | Egypt | Cohort study | 2000–2010 | 112 RCC (pT3+pT4) | 10 | 59 | 24 months | RFS | 7 |
Schrader | 2009 | Germany | Cohort study | 1990–2005 | 780 RCC | 67 | 64 | 5.44 years | CSS | 8 |
Anderson | 2011 | USA | Cohort study | 1988–2008 | 303 RCC (pT3) | 67 | 61.8 | 23.3 months | OS, CSS | 8 |
Verhoest | 2009 | France and Italy | Cohort study | 1997–2004 | 754 RCC (pT1+pT2) | 35 | 61 | 43 months | CSS | 9 |
Waalkes | 2010 | Germany | Cohort study | 1990–2005 | 1678 RCC | 149 | 62 | 5.4 years | CSS | 7 |
Brookman-Amissah | 2010 | Germany | Cohort study | 1992–2006 | 834 RCC | 90 | 62.2 | 79 months | CSS | 9 |
